A Markov model assessing the cost-effectiveness of various anti-vascular endothelial growth factor drugs and panretinal photocoagulation for the treatment of proliferative diabetic retinopathy
PRP is likely to be more cost-effective than anti-VEGFs for PDR. However, the results should be interpreted with caution given the scarcity of long-term visual outcomes with anti-VEGFs in this population. Further research on long-term visual outcomes may resolve these uncertainties.
Authors
- Philip I. Burgess (ORCID: https://orcid.org/0000-0002-3959-2299)
- Hannah Tebbs
- Syed Mohiuddin (ORCID: https://orcid.org/0000-0003-4585-3392)
- Lindsay Claxton (ORCID: https://orcid.org/0000-0002-1795-7568)
- Christiana Dinah (ORCID: https://orcid.org/0000-0002-0815-4771)
- Noemi Lois (ORCID: https://orcid.org/0000-0003-2666-2937)
- Kirsty Luckham (ORCID: https://orcid.org/0009-0009-2131-6243)
Institutions
- Queen's University Belfast (GB)
- University of Liverpool (GB)
- Aintree University Hospitals NHS Foundation Trust (GB)
- London North West Healthcare NHS Trust (GB)
- National Institute for Health and Care Excellence (GB)
Publication Details
- Journal
- Eye
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1038/s41433-025-03641-4
- Citations
- 7
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 11.95